We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

27 hedge funds and large institutions have $123M invested in MoonLake Immunotherapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

9% more capital invested

Capital invested by funds: $113M → $123M (+$10.6M)

1.19% more ownership

Funds ownership: 95.77% → 96.95% (+1.2%)

40% less funds holding

Funds holding: 45 → 27 (-18)

72% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 25

Holders
27
Holders Change
-18
Holders Change %
-40%
% of All Funds
0.43%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
8
Reduced
2
Closed
25
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$28.4M
2
BCM
Beryl Capital Management
California
+$4.57M
3
6CM
683 Capital Management
New York
+$1.99M
4
WAM
Weiss Asset Management
Massachusetts
+$1.62M
5
AWG
Alpha Wave Global
New York
+$1.4M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$10M
2
BC
Boxer Capital
California
-$3.96M
3
OCA
Octagon Capital Advisors
New York
-$3.96M
4
CS
Credit Suisse
Switzerland
-$3.68M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$19K +$16.8K +1,692 New
CS
27
Clear Street
New York
$9K +$7.97K +801 New
Adage Capital Partners
28
Adage Capital Partners
Massachusetts
– -$10M -1,011,589 Closed
BC
29
Boxer Capital
California
– -$3.96M -400,000 Closed
OCA
30
Octagon Capital Advisors
New York
– -$3.96M -400,000 Closed
CS
31
Credit Suisse
Switzerland
– -$3.68M -371,849 Closed
Alyeska Investment Group
32
Alyeska Investment Group
Illinois
– -$3.17M -320,000 Closed
ACM
33
Altium Capital Management
New York
– -$2.47M -250,000 Closed
TCM
34
Tenor Capital Management
New York
– -$1.99M -201,152 Closed
CIM
35
Cowen Investment Management
New York
– -$1.98M -200,000 Closed
BCM
36
BlueCrest Capital Management
Jersey
– -$1.48M -150,000 Closed
SCM
37
Silverarc Capital Management
Massachusetts
– -$1.3M -131,823 Closed
KC
38
Kryger Capital
United Kingdom
– -$998K -100,913 Closed
CCFM
39
Cohen & Co Financial Management
New York
– -$989K -100,000 Closed
JG
40
Jefferies Group
New York
– -$774K -78,308 Closed
SSA
41
Schonfeld Strategic Advisors
New York
– -$496K -50,106 Closed
PCM
42
Prelude Capital Management
New York
– -$495K -50,000 Closed
TD Asset Management
43
TD Asset Management
Ontario, Canada
– -$443K -44,766 Closed
MF
44
Magnetar Financial
Illinois
– -$370K -37,385 Closed
ECM
45
ExodusPoint Capital Management
New York
– -$249K -25,200 Closed
RCM
46
Radcliffe Capital Management
Pennsylvania
– -$249K -25,130 Closed
CC
47
Caxton Corporation
New Jersey
– -$158K -16,009 Closed
HF
48
HRT Financial
New York
– -$141K -14,258 Closed
RL
49
RPO LLC
Connecticut
– -$135K -13,600 Closed
Morgan Stanley
50
Morgan Stanley
New York
– -$133K -13,449 Closed
1
2
3

MLTX Hedge Fund Activity: Q1 2022 in Review

27 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2022, worth a combined $123M — up 9.4% from $113M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of MLTX and 7 opened new positions — a net loss of 18 holders — while 2 trimmed existing stakes and 8 added.

The largest buyer was Cormorant Asset Management, adding an estimated $28.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $10M sold.

  • 27 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2022, down from 45 in Q4 2021.
  • Funds reported $123M of MoonLake Immunotherapeutics stock for Q1 2022, up 9.4% quarter-over-quarter.
  • 7 funds opened new MoonLake Immunotherapeutics positions in Q1 2022 and 25 closed out, a net change of -18 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q1 2022 was Cormorant Asset Management, an estimated $28.4M added.
  • The largest MoonLake Immunotherapeutics seller in Q1 2022 was Adage Capital Partners, an estimated $10M sold.

Based on aggregated 13F filings for Q1 2022.